A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
A Phase 1, Single-Center, Open-Label Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
Lead SponsorSpyryx Biosciences, Inc.
StatusCompleted No Results Posted
Ascending dose, 7-day, open label safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.
Inclusion Criteria: Confirmed diagnosis of CF FEV1 ≥ 40% predicted normal Stable CF lung disease Non-pregnant, non-lactating females Exclusion Criteria: Significant unstable co-morbidities within 28 days of screening as judged by the Investigator. Has received an investigational drug within the past 30 days